Tag - NVAX

Developments

Novavax sets first-in-human trial for coronavirus vaccine candidate in mid-May

Novavax (NASDAQ:NVAX) identified a coronavirus vaccine candidate, NVX-CoV2373, using its nanoparticle technology, and will initiate a first-in-human trial in mid-May. Novavax’s Matrix-M adjuvant will be incorporated...

April 8, 2020

Markets

Ladenburg ups Novavax PT to $24 from $16

Ladenburg Thalmann raised its price target for Novavax (NASDAQ:NVAX) to $24 from $16 after the company reported impressive pivotal results with its lead asset, NanoFlu. The stock closed at $12.77 on March 24. Analyst...

March 25, 2020

Developments

Novavax Phase 3 ResVax trial misses primary endpoint

Novavax (NASDAQ:NVAX) reported that its Phase 3 PREPARE studyfor ResVax, a RSV (respiratory syncytial virus) F vaccine, did not meet its primary objective of preventing medically significant RSV lower respiratory tract...

March 1, 2019

Feature

Novavax to report key vaccine data in first quarter

Novavax (NASDAQ:NVAX) is scheduled to report pivotal data in the current quarter for ResVax, its RSV (respiratory syncytial virus) F vaccine, using aluminum phosphate as an adjuvant, in infants via maternal immunization.

January 22, 2019

Tag - NVAX

Novavax sets first-in-human trial for coronavirus vaccine candidate in mid-May

Ladenburg ups Novavax PT to $24 from $16

Novavax Phase 3 ResVax trial misses primary endpoint

Novavax to report key vaccine data in first quarter

General

More